Home / People / Ruth Mahfoozpour
Picture of Ruth Mahfoozpour

Ruth Mahfoozpour

Associate

CMS Reich-Rohrwig Hainz
Rechtsanwälte GmbH
Gauermanngasse 2
1010 Vienna
Austria
Languages German, English, French

Field of activity

Ruth Mahfoozpour works as an associate primarily in the field of intellectual property (IP) and industrial property protection. She has been with CMS Reich-Rohrwig Hainz since 2017 and advises clients on a wide range of issues including unfair competition, media and IP law.

Previous professional experience / training

During her legal studies at the University of Vienna, she worked at the Institute of Civil Procedure Law and later she gained experience as an associate for dispute resolution & litigation. Within the scope of her practice in the field of IP and unfair competition law, she regularly advises clients in matters pending in courts. In addition, in 2018-19 Ruth Mahfoozpour also completed a master's degree at King's College London with a focus on IP and arbitration.

Ruth Mahfoozpour's clients include the life science, media and consumer goods industries as well as the protection of trade secrets and trademark rights.

more less

Education

  • 2015 – Internship, Austrian Economic Chamber in Strasbourg
  • 2014-2015 – Teaching assistant, Department of Civil Procedure, University of Vienna
more less

Memberships

  • YAAP – Young Austrian Arbitration Practitioners
more less

Publications

  • Christian Klausegger/Ruth Mahfoozpour, 10 Years Austrian Yearbook on International Arbitration, in AUSTRIAN YEARBOOK ON INTERNATIONAL ARBITRATION 2016 [311] (Klausegger, Klein, Kremslehner, Petsche, Pitkowitz, Power, Welser & Zeiler, eds., 2016)
more less

Feed

Show only
16/04/2020
New re­port­ing ob­lig­a­tion for sup­ply short­ages of pre­scrip­tion medi­cines
Who is sub­ject to the re­port­ing ob­lig­a­tion? And what hap­pens if the ob­lig­a­tion to re­port short­ages of pre­scrip­tion medi­cines is not com­plied with?
17 April 2020
Man­dat­ory no­ti­fic­a­tion of sup­ply short­ages of pre­scrip­tion medi­cines
As of April 1st, 2020, mar­ket­ing au­thor­iz­a­tion hold­ers must no­ti­fy to the Aus­tri­an Fed­er­al Of­fice for Safety in Health Care (BASG) if pre­scrip­tion medi­cines are not avail­able or only avail­able in lim­ited...